Sanara MedTech (NASDAQ:SMTI) Trading Up 0.8% – Here’s What Happened

Sanara MedTech Inc. (NASDAQ:SMTI) traded up 0.8% on Monday . The company traded as high as $19.90 and last traded at $19.64. 65,314 shares traded hands during mid-day trading, an increase of 14% from the average session volume of 57,330 shares. The stock had previously closed at $19.48.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Sanara MedTech in a report on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $41.00.

Sanara MedTech Price Performance

The firm has a 50 day moving average price of $21.05 and a 200 day moving average price of $25.32. The stock has a market capitalization of $174.80 million, a PE ratio of -4.65 and a beta of 1.04. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SMTI. Vanguard Group Inc. grew its stake in shares of Sanara MedTech by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after acquiring an additional 6,049 shares during the period. Stonebridge Wealth Management LLC raised its stake in Sanara MedTech by 17.8% during the 4th quarter. Stonebridge Wealth Management LLC now owns 134,934 shares of the company’s stock worth $3,151,000 after acquiring an additional 20,353 shares during the period. Royal Bank of Canada raised its stake in Sanara MedTech by 127.3% during the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after acquiring an additional 65,887 shares during the period. Geode Capital Management LLC lifted its holdings in Sanara MedTech by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock valued at $1,846,000 after purchasing an additional 546 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after purchasing an additional 42,237 shares in the last quarter. 8.10% of the stock is owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.